Cyclica Inc. has completed a $2.25M Series A2 financing, an extension of the $2.4M Series A1 financing round that closed in September 2016.

Cyclica has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express.

Michael T.R. List, Principal at GreenSky Capital and member of the Cyclica Board of Directors, said: “We continue to believe in Cyclica’s ability to deliver on their strategy, execute on opportunities that are in front of them, and are confident in Cyclica’s success.”

Naheed Kurji, President and CEO added that: “In June 2017, we soft- launched our Software-as-a-Service platform at following requests from our clients and the market. This financing will help us continue, over the next 12 months, to focus on commercializing the platform globally.”